Met-Enkephalin 5mg - Research Peptide

Met-Enkephalin Description

CAS number (sequence): 58569-55-4 (Tyr-Gly-Gly-Phe-Met; [Met⁵]-enkephalin)
Molecular formula: C₂₇H₃₅N₅O₇S
Molecular weight: 573.67 g/mol (anhydrous free base)

Met-enkephalin is a small peptide naturally produced in the human body that helps manage pain signals. It forms through the breakdown of a larger precursor protein inside nerve cells and certain immune cells. Once active, the peptide attaches to specific receptors on cell surfaces to reduce how strongly pain messages travel through the nervous system.

It also influences cell division rates in growing tissues and tumors by slowing the progression of cells through their growth cycle. In the immune system, met-enkephalin adjusts the behavior of white blood cells, including T cells and natural killer cells, to support balanced responses.

Scientists have examined its effects in animal models of cancer, where it limits uncontrolled cell multiplication. Similar tests in animals with nerve inflammation show improvements in movement and reduced tissue damage.

Human studies have tested met-enkephalin in people with advanced cancers and certain immune-related conditions. The findings indicate that it can stabilize disease progression in some cases by working alongside the body’s own regulatory systems.

Research continues to clarify its roles and ways to apply it in peptide-based applications.

Biosynthesis and Peptide Processing

Met-enkephalin, the pentapeptide Tyr-Gly-Gly-Phe-Met, arises from proteolytic processing of proenkephalin, a 243-amino-acid precursor encoded by the PENK gene.

Proenkephalin undergoes sequential cleavage by prohormone convertases PC1/3 and PC2 at dibasic sites, followed by carboxypeptidase E trimming of C-terminal basic residues and, in select cases, further amidation or acetylation modifications that fine-tune bioactivity.

This biosynthetic pathway operates in neurons of the central and peripheral nervous systems, adrenal chromaffin cells, and various immune cell lineages, yielding multiple copies of met-enkephalin per precursor molecule alongside lesser amounts of leu-enkephalin and extended forms such as met-enkephalin-Arg-Phe.

Once released into the extracellular space via regulated exocytosis, the peptide encounters rapid degradation by membrane-bound and soluble peptidases, primarily neutral endopeptidase (NEP, also known as enkephalinase), aminopeptidases, and carboxypeptidases.

These catabolic steps limit the native peptide’s half-life to minutes, presenting a key consideration in peptide synthesis strategies aimed at research stabilization through backbone modifications, D-amino acid substitutions, or cyclization while preserving core pharmacophores.

Molecular Mechanism of Action

At the molecular level, met-enkephalin exerts its primary effects through activation of G-protein-coupled opioid receptors, predominantly the mu (MOR) and delta (DOR) subtypes, with lesser engagement of kappa receptors under high local concentrations.

Receptor ligation triggers Gi/o heterotrimeric G-protein dissociation, whereupon the Gαi subunit directly inhibits adenylyl cyclase isoforms, sharply lowering intracellular cyclic AMP levels.

Concomitant release of Gβγ subunits modulates voltage-gated ion channels:

• it inhibits N-type and P/Q-type calcium channels at presynaptic terminals,
• curtailing calcium influx required for vesicular neurotransmitter release,
• while simultaneously activating G-protein-coupled inwardly rectifying potassium (GIRK) channels that hyperpolarize the neuronal membrane.

The net outcome is presynaptic inhibition of excitatory transmitter release — including glutamate in nociceptive pathways and substance P in spinal dorsal horn circuits — together with postsynaptic dampening of neuronal excitability.

In parallel, mitogen-activated protein kinase (MAPK/ERK) cascades undergo transient phosphorylation downstream of receptor activation, contributing to longer-term adaptations in gene expression that reinforce analgesic signaling without invoking the profound receptor internalization or desensitization seen with many synthetic agonists.

Opioid Growth Factor Pathway

An independent molecular pathway operates when met-enkephalin functions as the opioid growth factor (OGF).

Here it engages the OGF receptor (OGFr), a distinct integral membrane protein that translocates to the nucleus upon ligand binding.

This interaction upregulates the cyclin-dependent kinase inhibitors p16^INK4a and p21^WAF1/CIP1 at both transcriptional and post-translational levels.

Elevated p16 blocks cyclin D–CDK4/6 complexes, while p21 inhibits cyclin E–CDK2, collectively stalling retinoblastoma protein phosphorylation and halting progression from G0/G1 into S phase.

The result is a cytostatic rather than cytotoxic arrest that is fully reversible upon peptide withdrawal, serum-independent, and non-apoptotic at physiological concentrations.

This growth-regulatory axis operates in both normal renewing epithelia and neoplastic cells, where OGFr density often correlates inversely with proliferation rate.

Cross-talk between the classical opioid receptor pathways and the OGF–OGFr axis occurs in immune and glial cells, where reduced cAMP can synergize with p21 induction to restrain excessive lymphocyte expansion while preserving effector functions.

Potential Research Applications

These dual molecular mechanisms underpin diverse potential applications in peptide research.

In nociception, met-enkephalin contributes to endogenous analgesia within descending inhibitory tracts originating in the periaqueductal gray and rostral ventromedial medulla, as well as within peripheral terminals of primary afferents where immune-derived peptide release modulates inflammatory pain.

Its ability to inhibit neurotransmitter overflow at spinal and supraspinal synapses positions it as a template for designing peptidomimetics that achieve targeted pain signaling modulation with minimal reward pathway engagement.

In oncology research, the OGF–OGFr axis offers a non-cytotoxic strategy to restrain tumor proliferation across multiple lineages, including:

• pancreatic ductal adenocarcinoma,
• hepatocellular carcinoma,
• and certain sarcomas.

This occurs by restoring cell-cycle checkpoints that are frequently disrupted in malignant cells.

Immunomodulatory applications stem from met-enkephalin’s capacity to down-regulate regulatory T-cell suppressive activity while enhancing natural killer cell cytotoxicity and shifting cytokine profiles away from excessive pro-inflammatory dominance.

This profile suggests utility in autoimmune demyelinating research models, where unchecked T- and B-cell proliferation drives tissue damage, and in supportive recovery models following chemotherapy or viral infections where immune reconstitution is desirable.

Additional avenues include modulation of stress-axis hyperactivity, hepatoprotection via reduced oxidative stress and inflammatory signaling in hepatocytes, and potential adjunctive roles in metabolic syndrome through influences on adipose browning and energy homeostasis.

Animal Research Findings

Extensive animal trial data illustrate these applications across rodent and other preclinical models.

In xenograft models of human pancreatic cancer implanted subcutaneously or orthotopically in athymic nude mice, daily or intermittent met-enkephalin administration significantly retards tumor volume expansion, decreases DNA synthesis rates measured by BrdU incorporation, and elevates intratumoral p16 and p21 protein levels without inducing necrosis or altering host body weight.

Parallel studies in syngeneic murine models of hepatocellular carcinoma demonstrate reduced metastatic burden and prolonged host survival, accompanied by increased tumor-infiltrating NK cells and decreased Treg populations within the tumor microenvironment.

Experimental autoimmune encephalomyelitis (EAE), the standard rodent model of multiple sclerosis induced by myelin oligodendrocyte glycoprotein immunization, responds robustly to met-enkephalin.

Treated animals exhibit:

• delayed disease onset,
• markedly lower clinical scores of paralysis,
• preserved myelin integrity on histological sections,
• normalized serum peptide levels,
• reduced astrocytic activation,
• and reduced microglial proliferation.

Electrophysiological recordings in these models confirm restored conduction velocities across demyelinated fibers.

In acute and chronic inflammatory pain models — including carrageenan-induced paw edema, complete Freund’s adjuvant arthritis, and bone-cancer pain induced by tibial inoculation — systemic or intrathecal met-enkephalin attenuates mechanical allodynia and thermal hyperalgesia via both peripheral opioid receptor occupancy on immune cells and central presynaptic inhibition in the dorsal horn.

Stress paradigms in rodents and avian species further reveal that exogenous met-enkephalin blunts corticosterone surges and normalizes adrenal proenkephalin expression, indicating feedback regulation within the hypothalamic–pituitary–adrenal axis.

Collectively, these preclinical datasets establish concentration-dependent, receptor-mediated effects across pain, neoplasia, autoimmunity, and stress-related endpoints while highlighting the peptide’s rapid clearance as the principal pharmacokinetic limitation addressed in synthetic optimization programs.

Human Research Findings

Human trial summaries, drawn from open-label and controlled investigations, reinforce translational potential while underscoring safety in peptide research contexts.

In phase I escalation studies involving patients with advanced unresectable pancreatic adenocarcinoma who had progressed on standard chemotherapy, weekly intravenous infusions of met-enkephalin proved well tolerated, with no grade 3 or 4 adverse events attributable to the peptide and no evidence of opioid-related central effects.

Subsequent phase II open-label evaluation in a cohort of 24 such patients demonstrated objective tumor stabilization or regression in a majority of participants surviving beyond two months, coupled with median survival extension approximately threefold relative to historical controls receiving best supportive care alone.

Plasma met-enkephalin levels rose transiently post-infusion and correlated with clinical benefit.

Parallel investigations in hepatocellular carcinoma patients similarly reported slowed radiographic progression and improved performance status.

For multiple sclerosis, observational data and small interventional cohorts using low-dose naltrexone regimens — known to transiently elevate endogenous met-enkephalin — documented increased serum peptide concentrations, reduced fatigue scores on validated quality-of-life instruments, and stabilization of Expanded Disability Status Scale scores over periods extending to several years.

These changes coincided with decreased MRI lesion activity in some participants.

A combination formulation incorporating met-enkephalin with an adrenocorticotropic hormone fragment advanced to phase II/III evaluation in relapsing-remitting multiple sclerosis and moderate-to-severe COVID-19, where immunomodulatory endpoints included enhanced NK cell function and tempered cytokine release without immunosuppression.

Additional exploratory work in advanced cancer settings has linked met-enkephalin administration to restored lymphocyte proliferative responses post-chemotherapy and reduced Treg-mediated suppression, supporting its role as an adjunctive bioregulatory peptide.

Across these studies, the peptide’s endogenous origin and short duration of action translate into a favorable tolerability profile suitable for chronic peptide research applications, particularly when synthesis efforts focus on half-life extension without loss of OGFr or classical opioid receptor selectivity.

Peptide Synthesis and Structure–Activity Research

In peptide synthesis laboratories specializing in advanced research candidates, met-enkephalin serves as a prototypical scaffold for structure–activity refinement.

Solid-phase or solution-phase approaches routinely incorporate Fmoc or Boc strategies, with careful selection of side-chain protection to prevent racemization at the Phe residue during activation.

Post-assembly modifications include:

• N-methylation of Gly residues,
• replacement of Met with norleucine or isosteric sulfoxide variants,
• and backbone cyclization via lactam bridges.

These strategies have yielded analogs retaining OGFr affinity while resisting NEP and aminopeptidase degradation.

Such chemical biology insights directly inform translational research, enabling sustained receptor occupancy in vivo and broadening the functional window for applications in oncology, neurology, and immunology.

Future directions will likely integrate stabilized congeners into targeted delivery platforms, such as nanoparticle conjugates or cell-penetrating peptide fusions, to achieve tissue-specific accumulation while exploiting the molecule’s inherent ability to coordinate analgesia, growth control, and immune homeostasis at the molecular level.